Clinical Research Directory

Inclusion Criteria: * Histologically proven BTC, including intrahepatic cholangiocarcinoma, extrahepatic bile duct cancer, gallbladder cancer, ampulla of vater cancer * Unresectable or recurrent * chemotherapy -naïve for their unresectable or recurrent cancer (Previous expose to adjuvant chemotherapy is allowed) * should have measurable lesion * ECOG 0, 1 * Without previous expose to immune-oncology agents including anti-CTLA4, anti-PD1, anti-PDL1, etc * Adequate organ function : ANC\>1500/mm3, platelet\>100K/mm3, HgB\>9 g/Dl, bilirubin\<1.5 x ULN, ALT/AST\<2.5 X UNL, (in case of liver metastasis, \<5 Xunl), Cr\<1.5 mg/Dl * Informed consent Exclusion Criteria: * Previous treatment for unresectable or recurrent cancer * Under immunosuppressive agents higher than equivalent dose of prednisone 10mg/day * Uncontrolled disease such as current active infection, congestive heart failure, uncontrolled hypertension, unstable angina, arrhythmia, interstitial lung disease * Current active pulmonary tuberculosis * Current active hepatitis B or hepatitis C (simple carrier is allowed) * anti-HIV (+) * Pregnant, breast-feeding women